AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02231853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVSTr
Description: PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr.
Study NCT01019317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 0.5 grams/m\^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients > 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 3).
Study NCT01019317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 15 mg/m\^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients > 65 years and 3 days in patients with PS > 3).
Study NCT03780426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tSMS
Description: Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
Study NCT03780426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham
Description: A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
Study NCT01037881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Description: comparison of different dosages of drug
Study NCT01037881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 29102
Description: comparison of different dosages of drug
Study NCT01037881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel®
Description: comparison
Study NCT04474223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In mother in whom 2° AVB or AV interval >170 ms has been diagnosed in the fetus:~Dexamethasone 8 mg po/day for 10 days. Then dexamethasone 4 mg po/ day through 28 weeks 6 days gestational age (GA); then 3 mg/day from 29 wks 0 days to 29 wks 6 days GA; then 2 mg/day until delivery
Study NCT04474223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: In a mother in whom 2° AVB has been diagnosed in the fetus:~One dose of IVIG \[1g/kg of maternal weight (max dose 70 g)\] at diagnosis of 2° AVB (within 12 hours of detection by mother via home monitoring and within 6 hours of confirmation by echocardiogram). A fetal AV interval > 170 ms will not be treated with maternal IVIG, only dexamethasone.
Study NCT00458809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
Study NCT01326533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
Study NCT01326533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirteen weeks of oral placebo provided as capsules
Study NCT00477854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium Picolinate
Description: Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
Study NCT00628251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: 400mg Oral twice daily
Study NCT00628251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Doxorubicin
Description: 50mg/m2 Monthly Intravenous
Study NCT00628251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: 200mg oral twice daily
Study NCT02622880 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immunomodulatory supplement
Description: Experimental Group (immunomodulatory supplement STUDY)
Study NCT02622880 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IMPACT
Description: IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
Study NCT04046133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
Study NCT01971203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seroquel xr
Description: Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
Study NCT01971203 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: 16 weeks of treatment
Study NCT02166866 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Questionairre and Education
Study NCT02037646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative fecal immunochemical test
Description: This test measures the amount of blood within the submitted stool specimen
Study NCT02037646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quantitative fecal immunochemical test
Description: This test detects presence or absence of blood within a submitted stool specimen.
Study NCT02037646 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
Study NCT02037646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cost analysis
Description: Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
Study NCT02037646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anxiety scores
Description: Hospital Anxiety and Depression Scale (HADS) questionnaire
Study NCT02037646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient satisfaction scores
Description: A 5-point patient satisfaction score will be documented at each patient visit related to screening.
Study NCT00728481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
Study NCT00728481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose \[Splenda-registered trademark\]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
Study NCT00954525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Erlotinib
Description: Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
Study NCT00954525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C
Description: 50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
Study NCT02645513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Malaria text message reminders to health workers
Description: Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
Study NCT02645513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Malaria, pneumonia, and diarrhea text message reminders to health workers
Description: Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
Study NCT02645513 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No text message reminders
Study NCT02873507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI of donor liver prior to transplant
Description: MRI of the on ice donor liver within the transport cooler on its way to the operating room
Study NCT02906839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
Study NCT00350805 — intervention group
Intervention type: PROCEDURE
Intervention: EEG
Description: One 20 minutes session
Study NCT01832363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HXe MRI guided treatment sequence for BT
Description: HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
Study NCT01832363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment sequence for BT (control)
Description: Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
Study NCT00778622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
Study NCT03641053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey
Description: Substance is given topically after the wound has been sutured
Study NCT03641053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine
Description: Substance is given topically after the wound has been sutured
Study NCT03641053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin gauze
Description: Substance is given topically after the wound has been sutured
Study NCT02831205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everolimus-eluting bioresorbable vascular (Absorb) scaffold
Study NCT02831205 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: everolimus-eluting cobalt-chromium (Xience) stent
Study NCT04003935 — intervention group
Intervention type: OTHER
Intervention: Juice Plus+ Complete
Description: Plant-based smoothie; maintaining habitual diet.
Study NCT04003935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Juice Plus+ Premium
Description: Fruit and vegetable juice concentrate; maintaining habitual diet.
Study NCT00078754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine capsules by mouth, up to 60 mg daily
Study NCT00078754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Divalproex ER capsules by mouth, up to 3000 mg daily
Study NCT00078754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules by mouth, up to 8 capsules daily
Study NCT00147823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vitoss Alone
Description: Synthetic bone graft material
Study NCT00147823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitoss with Bone Marrow Aspirate
Description: Vitoss mixed with Bone Marrow aspirate
Study NCT01968070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY3127760
Description: Administered orally
Study NCT01968070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127760
Description: Administered orally
Study NCT01968070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3127760
Description: Administered orally
Study NCT01968070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally
Study NCT01968070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01968070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01968070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02823626 — intervention group
Intervention type: DRUG
Intervention: Spironolactone and patiromer
Description: High dose spironolactone with or without patiromer based on the patient's baseline potassium
Study NCT00775450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal
Study NCT00775450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular
Study NCT00775450 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular
Study NCT04171843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.
Study NCT03655379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal nasal Doppler by ultrasonography
Description: Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns and measurements will be performed
Study NCT00821431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Device
Description: Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:~Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.~Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day.
Study NCT00821431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
Study NCT02821468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droglican
Description: Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
Study NCT02821468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol or oral NSAIDs excluding COX2 inhibitors
Study NCT03605563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling
Description: Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions.
Study NCT03605563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction.
Study NCT03552822 — intervention group
Intervention type: OTHER
Intervention: ERAS Protocol Implementation
Description: Implementation of ERAS Protocol Implementation
Study NCT02646748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV Q3W.
Study NCT02646748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: Itacitinib tablets administered orally once daily.
Study NCT02646748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB050465
Description: INCB050465 tablets administered orally once daily.
Study NCT03537599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03537599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Given via infusion
Study NCT03537599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01283698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: LAS 41004 dosage 1
Description: dosage 1, once daily
Study NCT01283698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: LAS 41004 dosage 2
Description: LAS 41004 dosage 2, once daily
Study NCT01283698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: LAS 41004 dosage 3
Description: dosage 3, once daily
Study NCT01283698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: placebo
Description: once daily
Study NCT01283698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Active Comparator,once daily
Study NCT02263534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single incision minisling
Description: midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed
Study NCT02263534 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tension free vaginal tape
Description: midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
Study NCT01431534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m\^2, 28 mg/m\^2, or 33 mg/m\^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
Study NCT01382264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Assisted Decision Support
Description: Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
Study NCT01704833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)
Description: The PFCBT is a 15-week Program that includes weekly group and individual sessions.
Study NCT02463188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Fitness Intervention
Description: The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
Study NCT00194844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Caring
Description: Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.